Business Context and Reporting Period
This Form 8-K was filed by Intelligent Bio Solutions Inc. on July 23, 2024. The report discloses corporate governance actions regarding executive compensation approved by the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive base salaries:
- CEO (Harry Simeonidis): Annual base salary increased from USD $270,600 to USD $369,600.
- CFO (Spiro Sakiris): Annual base salary increased from USD $237,600 to USD $270,600.
- Currency Conversion: Salaries are paid in Australian dollars and converted at a rate of 1 AUD to 0.66 USD.
Material Changes
The primary material change is the retroactive approval of salary increases for the CEO and CFO, effective April 1, 2024. No other material changes to financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, risk factors, contingencies, or unusual items. The document is strictly limited to the disclosure of the compensation adjustment.
Investor Verification Checklist
- Verify the retroactive effective date of April 1, 2024, for the salary adjustments.
- Confirm the total cash impact of the salary increases on the company's operating expenses for the fiscal year.
- Review the Compensation Committee's rationale for the increases, which is not detailed in this filing.
- Check subsequent filings for any related stock-based compensation adjustments or performance metrics tied to these roles.